Protagonist Therapeutics (PTGX) Net Cash Flow (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Net Cash Flow data on file, last reported at $65.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 54.05% year-over-year to $65.3 million; the trailing twelve-month figure through Mar 2026 stood at $54.1 million (up 264.43% YoY), and the FY2025 full-year result was $31.2 million, up 134.87% from the prior year.
• Net Cash Flow improved to $65.3 million in Q1 2026, from $14.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $183.1 million in Q2 2024 to a low of -$224.5 million in Q3 2024.
• A 5-year average of $4.1 million and a median of $1.9 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 4524.55% in 2024 and jumped 399.48% in 2025, its largest moves.
• Tracing PTGX's Net Cash Flow over 5 years: stood at -$27.1 million in 2022, then tumbled by 61.34% to -$43.8 million in 2023, then increased by 22.67% to -$33.9 million in 2024, then soared by 143.33% to $14.7 million in 2025, then surged by 345.07% to $65.3 million in 2026.
• Business Quant data shows PTGX's Net Cash Flow at $65.3 million in Q1 2026, $14.7 million in Q4 2025, and -$54.8 million in Q3 2025.